Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nuvilex Inc. (PMCB : NSDQ)

• Company Description    PharmaCyte Biotech, Inc. is a clinical stage biotechnology company. It is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). The Company's patented technology is used in the treatment of several types of cancer, including advanced, inoperable pancreatic cancer and diabetes. PharmaCyte Biotech, Inc., formerly known as Nuvilex, Inc., is based in United States. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $0.85 Daily Weekly Monthly 20 Day Moving Average: 49,039 shares Shares Outstanding: 6.80 (millions) Market Capitalization: $5.79 (millions) Beta: -0.20 52 Week High: $1.94 52 Week Low: $0.79 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.80% -17.03% 12 Week -5.32% -9.25% Year To Date -45.73% -52.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3960 HOWARD HUGHES PARKWAY SUITE 500 - LAS VEGAS,NV 89169 USA ph: 917-595-2850 fax: 917-595-2851 ir@pharmacyte.com http://www.pharmacyte.com

• General Corporate Information    Officers Joshua N. Silverman - Chief Executive Officer Carlos A. Trujillo - Chief Financial Officer Jonathan L. Schechter - Director Robert Weinstein - Director Michael M. Abecassis - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 71715X203 SIC: 2836 Fiscal Year Fiscal Year End: April Last Reported Quarter: 07/01/25 Next Expected EPS Date: 12/12/25 Share - Related Items Shares Outstanding: 6.80 Most Recent Split Date: 7.00 (0.00:1) Beta: -0.20 Market Capitalization: $5.79 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 12/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.13 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -164.29% vs. Previous Quarter: 64.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 10/31/25 - - 07/31/25 - -6.41 04/30/25 - 4.60 ROA 10/31/25 - - 07/31/25 - -5.77 04/30/25 - 3.76 Current Ratio 10/31/25 - - 07/31/25 - 18.01 04/30/25 - 7.68 Quick Ratio 10/31/25 - - 07/31/25 - 18.01 04/30/25 - 7.68 Operating Margin 10/31/25 - - 07/31/25 - - 04/30/25 - - Net Margin 10/31/25 - - 07/31/25 - - 04/30/25 - - Pre-Tax Margin 10/31/25 - - 07/31/25 - - 04/30/25 - - Book Value 10/31/25 - - 07/31/25 - 6.41 04/30/25 - 7.56 Inventory Turnover 10/31/25 - - 07/31/25 - - 04/30/25 - - Debt-to-Equity 10/31/25 - - 07/31/25 - 0.00 04/30/25 - 0.00 Debt-to-Capital 10/31/25 - - 07/31/25 - 0.00 04/30/25 - 0.05

Powered by Zacks Investment Research ©